Ranger Investment Management L.P. Has $20.89 Million Holdings in Repligen Corporation $RGEN

Ranger Investment Management L.P. decreased its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 24.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 167,920 shares of the biotechnology company’s stock after selling 54,795 shares during the quarter. Ranger Investment Management L.P. owned approximately 0.30% of Repligen worth $20,886,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its holdings in shares of Repligen by 4.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 396,150 shares of the biotechnology company’s stock valued at $50,406,000 after acquiring an additional 18,250 shares in the last quarter. Nuveen LLC bought a new position in Repligen in the first quarter valued at approximately $35,536,000. HighTower Advisors LLC increased its position in shares of Repligen by 15.3% during the 1st quarter. HighTower Advisors LLC now owns 5,828 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 774 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Repligen by 44.2% during the 1st quarter. Russell Investments Group Ltd. now owns 83,874 shares of the biotechnology company’s stock worth $10,672,000 after purchasing an additional 25,702 shares during the last quarter. Finally, Neuberger Berman Group LLC bought a new stake in shares of Repligen during the 1st quarter worth approximately $693,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Repligen

In other news, COO James Bylund sold 2,191 shares of Repligen stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony Hunt sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the completion of the sale, the director directly owned 80,743 shares of the company’s stock, valued at approximately $12,483,675.23. The trade was a 19.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 49,382 shares of company stock valued at $7,676,802. 1.20% of the stock is currently owned by insiders.

Repligen Stock Down 2.6%

Shares of RGEN opened at $157.39 on Friday. The firm has a market cap of $8.86 billion, a P/E ratio of 7,873.44, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The firm’s 50-day simple moving average is $156.00 and its 200 day simple moving average is $134.58.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The firm had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. During the same period last year, the business posted $0.43 earnings per share. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Hsbc Global Res upgraded shares of Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Wednesday, September 3rd. Barclays lifted their price target on Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.85.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.